The primary aim from the demo was to ascertain if Anastrozole could lengthen the period of “disorder-free survival” to the participating clients. Disorder-free survival is outlined as the period of time just after medications and/or treatment plans are stopped before the individual’s cancer returns. Over the trial, researchers tracked events